Navigation Links
ProMetic announces scale-up of prion removal resin in plasma product for biopharmaceutical use
Date:1/23/2008

- First phase of development of product to reduce risk of variant

Creutzfeldt-Jakob Disease from plasma product completed on schedule

- Scale-up phase worth $ 1 M to ProMetic - Multi-million dollar long-term agreement to supply prion removal affinity

resin following regulatory approval anticipated by mid-2008

MONTREAL and CAMBRIDGE, United Kingdom, Jan. 23 /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic") announces that its UK-based subsidiary, ProMetic BioSciences Ltd ("PBL"), has successfully completed the first phases of development utilizing Pathogen Removal and Diagnostic Technologies Inc.'s ("PRDT") ligand technology for prion binding and removal from a plasma product for biopharmaceutical use marketed by a major European plasma fractionator. The program, which is progressing on schedule with expected completion of the scale-up phase in June 2008, is worth approximately $ 1 M to ProMetic. This will be followed by a multi-million dollar long-term supply agreement for the prion reduction resin. The supply agreement is in final stage of negotiation and commercial quantities of resin supply could commence as soon as mid-2008, assuming regulatory approval of the product.

The incorporation in this new application of PRDT's proprietary ligand technology, which is licensed exclusively to PBL, ensures the removal of any abnormal prion proteins that may be present in donated plasma. This additional process will add another level of safety to the already established treatment protocols and is particularly relevant since there is no commercially available diagnostic test for detection of the blood-borne form of the variant Creutzfeldt-Jakob disease ("vCJD") agent.

"We have now demonstrated that the use of the prion reduction technology in process applications is practical," stated Dr. Peter Edwardson, Vice-President, Medical Technologies of ProMetic. "We have already commenced scale
'/>"/>

SOURCE PROMETIC LIFE SCIENCES INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies
2. Vapotherm(R) Announces Validation of U.S. Patent
3. Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders
4. Abbott Announces Approval of First Fully Automated Blood Screening Test for HTLV-I/HTLV-II
5. Elekta Announces First Two Clinical Sites Using VMAT Cancer Treatment Capability
6. Amarin Provides Business Update and Announces Implementation of Reverse Stock Split
7. Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
8. Peptimmune Announces First Close of Series D Private Financing
9. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
10. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
11. Vasogen Announces 2007 Year-End Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014 China Biologic Products, ... a leading fully integrated plasma-based biopharmaceutical company in ... its majority-owned subsidiary, Shandong Taibang Biological Products Co. ... from the China Food and Drug Administration (the ... As previously disclosed in the Company,s public filings, ...
(Date:12/24/2014)... PARIS and NEW YORK ... data from its open-label pilot study of mazindol in ... Design, Development and Therapy in December 2014 . ... of mazindol in children with attention deficit/hyperactivity disorder" ( ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) ...
(Date:12/22/2014)... 22, 2014 GenomeDx Biosciences today announced that ... Classifier, a genomic test for prostate cancer, was able ... managed by radical prostatectomy without adjuvant therapy. Although rapid ... uncommon, using tumor genomics to identify these men who ... an important advance. The study has been published ...
(Date:12/19/2014)... and Hershey, PA (PRWEB) December 19, 2014 ... BJCT), a leading developer and manufacturer of needle-free ... into an agreement with Immunomic Therapeutics, Inc. (“ITI”) ... needle-free injection device with its LAMP™ vaccine platform. ... option for an exclusive Worldwide license to the ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... of HER1, HER2 and HER3 Assays to Provide Unique ... Facilitate Development of Personalized Cancer Therapies, SOUTH SAN ... ) today announced that the company,s HER1,and HER3 Quantitative ... on Monogram,s VeraTag(TM) platform, the HER1 and,HER3 assays provide ...
... Meeting of Shareholders to be Reconvened on May 29, ... Therapeutics,Corporation (Nasdaq: UTHR ) (the Company) held its ... 2008. The Company,s,shareholders voted to approve the election of ... directors with terms expiring in 2011. The,Company,s shareholders also ...
... IRVINE, Calif., May 1 Edwards Lifesciences,Corporation (NYSE: ... and technologies to,treat advanced cardiovascular disease, will host ... 2008 beginning at 10:00 a.m. PT (1:00 pm,ET) ... A live webcast of the meeting will be ...
Cached Biology Technology:HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics 2HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics 3HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics 4HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics 5United Therapeutics Announces the Results of Its 2008 Annual Meeting of Shareholders 2United Therapeutics Announces the Results of Its 2008 Annual Meeting of Shareholders 3Edwards Lifesciences to Webcast Annual Stockholders Meeting 2
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... of the "Micro Market Monitor: North America Perimeter ... http://photos.prnewswire.com/prnh/20130307/600769 The ... at a CAGR of 3.6% from 2014 to 2019. ... this market, Canada is expected ...
(Date:12/17/2014)... DUBLIN , Dec. 15, 2014 Research ... announced the addition of the "Samsung Galaxy ... Analysis" report to their offering. ... on a totally different sensing technology than the ... a fingerprint sensor in its product. ...
(Date:12/17/2014)... Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ... – with the clinical data to back it up," ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... Scientists at the National Physical Laboratory (NPL) have ... that provides structural support to cells to aid growth ... regenerative medicine. The extracellular matrix (ECM) provides the ... all biological tissues. It is a complex nano-to-microscale structure ...
... be coming soon to an ocean near you. Sensorbots ... to open a new chapter in the notoriously challenging ... devices are being designed and developed in the laboratory ... of the Center for Biosignatures Discovery Automation at Arizona ...
... hatcheries on salmon is so profound that in just one ... prosper in the hatchery environment, at the cost of their ... These findings, published this week in Proceedings of the ... and natural selection that surprised researchers. They confirmed that ...
Cached Biology News:Sensing the deep ocean 2Sensing the deep ocean 3Sensing the deep ocean 4Sensing the deep ocean 5Evolution at warp speed: Hatcheries change salmon genetics after a single generation 2Evolution at warp speed: Hatcheries change salmon genetics after a single generation 3